Breyanzi (Lisocabtagene Maraleucel): Uses, Side Effects & Warnings

• Breyanzi is a CAR T-cell therapy that re-engineers a patient’s T-cells to target and destroy cancer cells expressing the CD19 protein.
• It is primarily used for adults with relapsed or refractory large B-cell lymphoma after two or more prior systemic therapies.
• The treatment involves collecting a patient’s T-cells, modifying them in a lab, and then re-infusing them into the patient.
• Major potential side effects include Cytokine Release Syndrome (CRS) and neurological toxicities (ICANS), requiring close monitoring in specialized centers.
• Due to significant risks, Breyanzi is administered under a Risk Evaluation and Mitigation Strategy (REMS) program.

What is Breyanzi (Lisocabtagene Maraleucel) and How It Works?

Breyanzi (lisocabtagene maraleucel) is a groundbreaking gene therapy classified as a chimeric antigen receptor (CAR) T-cell therapy. It represents a personalized approach to cancer treatment, utilizing the patient’s own immune system to combat specific types of B-cell lymphomas. This therapy involves several distinct steps, beginning with the collection of a patient’s T-cells through a process called apheresis.

Once collected, these T-cells are sent to a manufacturing facility where they are genetically modified to express a chimeric antigen receptor (CAR). This CAR is specifically engineered to recognize and bind to the CD19 protein, which is commonly found on the surface of cancerous B-cells. After modification, the now “CAR T-cells” are expanded in number and then re-infused back into the patient. Upon re-infusion, these modified T-cells proliferate and actively seek out and destroy cancer cells expressing the CD19 antigen, offering a targeted and potent anti-cancer response. This mechanism of action is a significant advancement in oncology, providing a new option for patients with limited treatment alternatives. According to the National Cancer Institute, CAR T-cell therapy has shown remarkable efficacy in specific hematologic malignancies.

The effectiveness of Breyanzi (lisocabtagene maraleucel) stems from its ability to create a living drug within the patient’s body. The CAR T-cells can persist for an extended period, potentially providing long-term surveillance against the targeted cancer cells. Before the infusion of the modified T-cells, patients typically undergo a short course of lymphodepleting chemotherapy. This chemotherapy helps to reduce the number of existing T-cells in the patient’s body, creating a more favorable environment for the infused CAR T-cells to expand and function effectively. The entire process, from cell collection to infusion, is meticulously managed by specialized medical teams to ensure patient safety and optimize therapeutic outcomes.

Breyanzi Uses and Treatment Information

Breyanzi uses and indications are specifically for adult patients with large B-cell lymphoma (LBCL) that is relapsed or refractory after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B). It offers a critical treatment option for individuals who have not responded to conventional therapies or whose cancer has returned after initial treatments, addressing a significant unmet medical need in this patient population.

The treatment journey with Breyanzi (lisocabtagene maraleucel) is a multi-step process that requires careful planning and coordination. The initial step involves apheresis, where a patient’s blood is drawn, and T-cells are separated and collected. These cells are then sent to a specialized facility for genetic modification and expansion. While the CAR T-cells are being manufactured, which can take several weeks, patients may receive bridging therapy to control their cancer. Prior to the CAR T-cell infusion, patients undergo lymphodepleting chemotherapy, typically fludarabine and cyclophosphamide, to prepare their body for the new cells. This preparation is crucial for the successful engraftment and expansion of the CAR T-cells.

The actual infusion of Breyanzi (lisocabtagene maraleucel) is a one-time intravenous administration, usually performed in an inpatient setting. Following the infusion, patients require close monitoring for several weeks in a specialized medical center due to the potential for severe side effects. A comprehensive Breyanzi patient guide is often provided to help individuals understand each stage of the treatment, what to expect, and how to recognize potential complications. This guide is an essential resource for patients and their caregivers, empowering them with detailed information on Breyanzi treatment and post-infusion care requirements.

Lisocabtagene Maraleucel Side Effects and Important Warnings

Like all potent therapies, Lisocabtagene Maraleucel side effects can be significant and require careful management. The most common and serious adverse events associated with Breyanzi include Cytokine Release Syndrome (CRS) and neurological toxicities, often referred to as Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). CRS is a systemic inflammatory response that can manifest with symptoms such as fever, chills, hypotension, hypoxia, and organ dysfunction. ICANS can present with a range of neurological symptoms, including confusion, aphasia, seizures, and impaired consciousness. Both CRS and ICANS typically occur within the first few weeks following infusion and can be life-threatening if not promptly recognized and treated.

Due to the potential for severe and life-threatening side effects, Breyanzi (lisocabtagene maraleucel) is administered under a Risk Evaluation and Mitigation Strategy (REMS) program. This program ensures that healthcare facilities and personnel are specially trained to manage the unique risks associated with CAR T-cell therapy. Patients must be monitored for at least 4 weeks after infusion for signs and symptoms of CRS and neurological toxicities. Other potential side effects include serious infections, prolonged cytopenias (low blood cell counts), and hypogammaglobulinemia, which can increase the risk of infection. Patients may also experience gastrointestinal issues, fatigue, and musculoskeletal pain.

Important Breyanzi drug warnings also include the risk of secondary malignancies, although this is a rare and long-term concern. Patients should be monitored for new cancers for at least 15 years following treatment. Additionally, Breyanzi can cause severe allergic reactions. Patients are advised to inform their healthcare provider of any pre-existing medical conditions or medications they are taking. Given the complexity and potential severity of these side effects, patients and their caregivers receive extensive education and support throughout the treatment process to ensure they understand the risks and the importance of adhering to monitoring schedules.

Frequently Asked Questions

What kind of cancer does Breyanzi treat?

Breyanzi (lisocabtagene maraleucel) is approved to treat certain types of large B-cell lymphoma (LBCL) in adults. Specifically, it is used for patients whose cancer has either returned (relapsed) or has not responded to previous treatments (refractory) after receiving two or more prior systemic therapies. This includes diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B).

How long does the Breyanzi treatment process take?

The entire Breyanzi treatment process, from initial cell collection (apheresis) to genetic modification and re-infusion, can take several weeks. The manufacturing of the CAR T-cells typically takes about 3-4 weeks. After infusion, patients require close monitoring in a specialized facility for at least 4 weeks to manage potential side effects like Cytokine Release Syndrome and neurological toxicities. The total duration can vary based on individual patient response and recovery.

Are there specific dietary restrictions or lifestyle changes needed during Breyanzi treatment?

While there are no universal strict dietary restrictions directly related to Breyanzi (lisocabtagene maraleucel) itself, patients are often advised to follow a neutropenic diet to reduce the risk of infection due to a weakened immune system from lymphodepleting chemotherapy. Lifestyle changes typically involve avoiding crowded places and individuals with infections, maintaining good hygiene, and refraining from driving for a period after infusion due to potential neurological side effects. All specific recommendations will be provided by the treating medical team.